Repligen Corporation · RGEN · FY2026 Q1 · Calendar Q2 2026
Repligen raises outlook after strong analytics and China growth
Repligen's Q1 analysis supports a constructive outlook: broad franchise growth, strong analytics demand, and China expansion were paired with raised full-year guidance. The key test is whether margin initiatives and capital-equipment demand develop as planned while ATF timing and gene-therapy headwinds persist.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about RGEN FY2026 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year revenue guidance to $803-$833 million and adjusted EPS guidance to $1.97-$2.05. The quarter also brought a transformation office targeting at least one point of annualized margin benefit by 2027, a Polymem divestiture, and a phased China OEM partnership beginning in 2027.
Guidance delta
Raised: full-year revenue guidance is $803-$833 million, with adjusted EPS guidance of $1.97-$2.05 and operating income guidance of $124-$132 million.
Key takeaways
- Q1 revenue was $194 million, up 15% year over year, with 11% organic growth and 160 basis points of operating-margin expansion.
- Analytics grew more than 50%, while proteins and services also delivered strong growth.
- China revenue nearly doubled, supported by regional execution and a new OEM partnership.
- The transformation office and Fit-for-Growth initiatives are intended to improve profitability over time.
Management priorities
- Execute transformation-office projects across manufacturing, product-line profitability, services, and IT.
- Roll out the China OEM partnership in phases starting in 2027.
- Launch next-generation analytics and PAT products, including FlowVDX and digital-twin-enabled filtration systems.
- Maintain capex at roughly 3%-4% of revenue while preserving capacity for strategic M&A.
Follow RGEN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationRepligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand.…
Historical context
All RGEN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CNC Centene Corp. | FY2026 Q3 · Calendar Q4 2026 | — | +1.7% | Centene raises 2026 EPS outlook as margins hold up |
| HCA HCA Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -5.3% | HCA volume growth holds, but payer mix and Medicaid weigh on outlook |
| NVS Novartis AG | FY2026 Q3 · Calendar Q4 2026 | — | +1.2% | Novartis raises profit outlook as priority brands drive Q3 growth |
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
Latest beats and misses
Who reports nextBeat on EPS
- VZFY2026 Q3 · October 26, 2026+3.1% EPS-3.5% move
- CXFY2026 Q3 · October 26, 2026+12.0% EPS-0.1% move
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
Missed on EPS
- PFGFY2026 Q3 · October 26, 2026-8.6% EPS+0.3% move
- WELLFY2026 Q3 · October 26, 2026-15.8% EPS-5.3% move
- KOFFY2026 Q3 · October 26, 2026-9.0% EPS-1.9% move
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
Get the RGEN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-27T16:00:44.889235+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T16:00:44.886385+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.